Replies to post #223611 on Avid Bioservices Inc (CDMO)

[biopharm]

Scott Antonia : Peregrine Pharmaceuticals KOL

Raising Target Price to $43.50 as CBMG Acquiring First U.S. Program: Yesterday, CBMG announced they are acquiring CD40LGVAX, an “off-the-shelf” lung adenocarcinoma vaccine in combination with Bristol-Myers Squibb’s (NYSE:BMY Not Rated) anti-PD-1 checkpoint inhibitor Nivolumab (Opdivo®) for clinical trials at the Moffitt Cancer Center. This represents CBMG’s first program in the United States, which will be led by the inventor, Scott Antonia, MD, Ph.D., of the Department Chair of Thoracic Oncology and Program Leader of the Immuno-Oncology Program at the Moffitt Cancer Center and a member of CBMG’s Scientific Advisory Board. The addition of CD40LGVAX to Nivolumab therapy may result in longer overall survival for non-squamous non-small cell lung cancer (NSCLC) patients that are PDL1 negative and may be synergistic for patients that are PDL1 positive. (see CD40LGVAX Vaccine in Combination with Nivolumab (Opdivo®))

Clinical Trials: CBMG’s lung adenocarcinoma vaccine CD40LGVAX will be combined with Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor Nivolumab (Opdivo®) in a 3 patient lead-in Phase I clinical trial followed by a randomized Phase II clinical trial in patients with Stage IV unresectable non-small cell lung (NSCLC) cancer. The clinical trials are expected to commence in H2’15.
...
...
http://lifetechcapital.com/ltc/category/covered-companies/

.... now which vaccine is this that mentions inventor Scott Antonia, Dr. Antonia has a P53 vaccine along with Peregrine related ties..

Inventors:
Antonia, Scott (Land O'Lakes, FL, US)
Gabrilovich, Dmitry I. (Tampa, FL, US)
Chada, Sunil (Missouri City, TX, US)
Menander, Kerstin B. (Bellaire, TX, US)


Title:
P53 VACCINES FOR THE TREATMENT OF CANCERS
Document Type and Number:
United States Patent Application 20150044240
Kind Code:
A1

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110875478&txt2find=scott|antonia|patent

...next generation GVAX vaccine’s (“CD40LGVAX”) related technologies

http://www.cellbiomedgroup.com/newsroom/definitive-agreement-to-acquire-cd40lgvax-vaccine/

so "related technologies" includes what?? anything to do with P53 ??

Dr. Antonia added to scientific advisory board of CBMG on April 30, 2015 and CBMG scoops them up June 12, 2015 --- and just trying to connect some dots here, and try to find out if it has anything to do with Dr. Antonias P53 vaccine patent ?? .. I just don't see any other patents listed under Dr. Antonia

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=114563294&txt2find=cbmg|scott|antonia

---------------

CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines.

http://www.ncbi.nlm.nih.gov/pubmed/10648420

----------------

BCL6 cooperates with CD40 stimulation and loss of p53 function to rapidly transform primary B cells

http://www.researchgate.net/publication/24379886_BCL6_cooperates_with_CD40_stimulation_and_loss_of_p53_function_to_rapidly_transform_primary_B_cells

----------------

Phosphatidylserine regulates the maturation of human dendritic cells.

PS liposomes inhibited the up-regulation of HLA-ABC, HLA-DR, CD80, CD86, CD40, and CD83, as well as the production of IL-12p70 by human DCs in response to LPS.

http://www.ncbi.nlm.nih.gov/pubmed/15322157